Malaria is a significant health problem in Africa, particularly in Uganda where malaria accounts for up to 50% of the country’s morbidity and mortality. Recent years have witnessed a surge in both national and international interest in reducing the malaria burden and thus willingness and ability to tackle this disease is currently at an unprecedented level. New funding, tools and leadership have emerged, and an effective class of new medicines, artemisinin combination therapies (ACTs), has been developed to replace failing medicines. Since 2004, there has been a strong commitment in many countries to make these artemisinin-based products more widely available.